|
Affiliation |
Faculty of Medicine College Hospital Clinical oncology |
|
Title |
Professor |
|
External Link |
|
HOSOKAWA Ayumu
|
|
|
Papers 【 display / non-display 】
-
The Efficacy and Safety of Nivolumab Plus mFOLFOX6 in Gastric Cancer with Severe Peritoneal Metastasis. Reviewed
Nakayama Y, Ando T, Takahashi N, Tsukada K, Takagi H, Goto Y, Nakaya A, Nakada N, Yoshita H, Motoo I, Ueda A, Ueda Y, Sakumura M, Kajiura S, Ogawa K, Hosokawa A, Yasuda I
Journal of clinical medicine 13 ( 3 ) 2024.1
Language：English Publishing type：Research paper (scientific journal)
DOI： 10.3390/jcm13030834
-
Takagi H., Kajiura S., Hosokawa A., Horikawa N., Terada I., Hata T., Kobayashi Y., Tsukioka Y., Yabushita K., Matsuo T., Yoshita H., Ueda A., Ogawa K., Ando T., Hayashi R., Yasuda I.
Traditional and Kampo Medicine 10 ( 3 ) 278 - 284 2023.9
Language：English Publishing type：Research paper (scientific journal) Publisher：Traditional and Kampo Medicine
Aim: 5-Fluorouracil/folinic acid and oxaliplatin plus bevacizumab (FOLFOX + BV) is a standard chemotherapy regimen for metastatic colorectal cancer (mCRC). This study was aimed at evaluating the preventive effects of shakuyakukanzoto against oxaliplatin-induced neurotoxicity associated with FOLFOX + BV administration. Methods: In this single-arm, open-label, phase II clinical trial, we enrolled patients with previously untreated, histologically confirmed mCRC from six hospitals in Japan who were aged 20 years and older and had an Eastern Cooperative Oncology Group performance status of 0–1. The patients received shakuyakukanzoto 2.5 g thrice daily, orally, until disease progression and/or unacceptable toxicity was noted. The primary endpoint was the incidence of neurotoxicity following oxaliplatin administration at a dose of 500 mg/m2. Neurotoxicity was evaluated according to the Neurotoxicity Criteria of Debiopharm (DEB-NTC). The trial was registered in the UMIN Clinical Trials Registry of Japan (UMIN000001853). Results: Forty-one non-pretreated mCRC patients were included between April 2009 and September 2013. At an oxaliplatin dose of 500 mg/m2, neurotoxicity of DEB-NTC grade 1–2 developed in 25.0% of patients; no patient had DEB-NTC grade 3 neurotoxicity. The most common grade 3/4 adverse events were neutropenia (34.1%), hypertension (24.4%), and fatigue (9.8%). The response rate of the 38 patients with measurable lesions was 55.2%. The median progression-free and overall survival was 14.9 and 35.2 months respectively. Conclusion: Shakuyakukanzoto substantially reduced oxaliplatin-induced neurotoxicity without negatively affecting tumor response or survival in FOLFOX + BV-treated patients with CRC.
DOI： 10.1002/tkm2.1389
-
Motoo I., Ando T., Hamashima T., Kajiura S., Sakumura M., Ueda Y., Murayama A., Ogawa K., Tsukada K., Ueda A., Suzuki N., Nakada N., Nakashima K., Hosokawa A., Yasuda I.
Frontiers in Oncology 13 1193533 2023.9
Language：English Publishing type：Research paper (scientific journal) Publisher：Frontiers in Oncology
Introduction: The efficacy of immune checkpoint inhibitors (ICIs) is heterogeneous at each metastatic site, and tumor progression pattern is associated with survival; however, it remains unclear in gastric cancer (GC). Therefore, we aimed to clarify the progression pattern in response to ICIs in patients with GC, and we analyzed its mechanism focusing on the intratumoral immune cells. Methods: Patients who received ICIs were retrospectively classified into non-systemic and systemic progression groups based on their radiological assessments. Moreover, the best percentage change in target lesions from each organ was compared. Results: Among 148 patients, the non-systemic progression group showed a significant improvement in overall survival (OS) compared with the systemic progression group (median, 5.6 months vs. 3.3 months; HR, 0.53; 95%CI, 0.32–0.89; p = 0.012). Poor performance status (HR, 1.73, 95%CI, 1.00–2.87) and systemic progression (HR, 3.09, 95%CI, 1.95–4.82) were associated with OS. Of all metastatic sites, the liver showed the poorest percentage change, and liver metastasis (OR, 2.99, 95%CI, 1.04–8.58) was associated with systemic progression. Hence, intratumoral CD8+ T-cell density was lower in patients with liver metastasis than in those without liver metastasis after ICIs, although the density of CD4+ T-cells (Th1, Th17, and Treg) and CD163+ cells (TAM) were not significantly different. Conclusion: The new progression pattern was associated with OS in GC. Liver metastasis may be a predictive factor of systemic progression during ICIs by regulating intratumoral CD8+ T-cells.
-
Kai K., Hamada T., Sato Y., Hiyoshi M., Imamura N., Yano K., Ikeda T., Ichihara A., Ogata S., Choijookhuu N., Hishikawa Y., Hosokawa A., Nanashima A.
Journal of Oncology 2023 1440257 2023.2
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Journal of Oncology
Background. Oxaliplatin (OX)-based chemotherapy induces sinusoidal obstruction syndrome (SOS) in the nontumorous liver parenchyma, which can increase the risk of liver resection due to colorectal liver metastasis (CRLM). The extracellular volume (ECV) calculated from contrast-enhanced computed tomography (CT) has been reported to reflect the morphological change of hepatic fibrosis. The present retrospective study aimed to evaluate the ECV fraction as a predictive factor for OX-induced SOS. Methods. Our study included 26 patients who underwent liver resection for CRLM after OX-based chemotherapy with a preoperative dynamic CT of appropriate quality. We investigated the relationship between the pathological SOS grade and the ECV fraction. Results. Overall, 26 specimens from the patients were graded with the SOS classification of Rubbia-Brandt et al. as follows: grade 0, n = 17 (65.4%); grade 1, n = 4 (15.4%); and grade 2, n = 5 (19.2%). No specimens showed grade 3 SOS. In a univariate analysis, the ECV fraction in grade 0 SOS was significantly lower than that in grade 1 + 2 SOS (26.3 ± 3.4% vs. 30.6 ± 7.0%; P = 0.025). The cutoff value and AUC value of the ECV fraction to distinguish between grades 0 and 1 + 2 were 27.5% and 0.771, respectively. Conclusions. Measurement of the ECV fraction was found to be a potential noninvasive diagnostic method for determining early-stage histopathological sinusoidal injury induced by OX-based chemotherapy.
DOI： 10.1155/2023/1440257
-
Factors, Including Clinical Trial Eligibility, Associated with Induction of Third-Line Treatment for Advanced Gastric Cancer. Reviewed
Ando T, Hosokawa A, Sakumura M, Motoo I, Kajiura S, Hirano K, Miwa T, Yokota T, Nakada N, Ueda Y, Ueda A, Tsukada K, Ogawa K, Nakaya A, Teramoto A, Nanjo S, Mihara H, Fujinami H, Fujii T, Yasuda I
Oncology 101 ( 1 ) 59 - 68 2023.1
Books 【 display / non-display 】
-
消化器がん化学療法 副作用マネジメント プロのコツ改訂第2版
柴田伸弘, 細川 歩（ Role： Joint author , 第III章 【副作用症状別】プロのコツ 3. 腎・泌尿器）
小松 嘉人(編). メジカルビュー社, 283-296 , 2019 2019
Language：Japanese Book type：General book, introductory book for general audience
-
特集I 大腸癌化学療法 大腸癌化学療法における血管新生阻害薬の位置づけ
中島孝治, 柴田伸弘、田原良博, 細川歩（ Role： Joint author）
消化器・肝臓内科, 5: 24-32, 2019 2019
Language：Japanese Book type：General book, introductory book for general audience
-
【逸脱症例から学ぶ がん薬物療法 標準治療の実践!】(第1章)がん薬物治療 再発大腸がん
米澤玲美, 細川 歩（ Role： Joint author , 第1章 がん薬物治療, 10. 再発大腸がん）
勝俣範之編, 48-50, 月刊薬事 61巻 第10号, 株式会社じほう 2019
Language：Japanese Book type：General book, introductory book for general audience
Presentations 【 display / non-display 】
-
消化器悪性腫瘍に対する薬物療法の進歩 当科における膵癌化学療法の現状 FOLFIRINOX療法とGEM/nab-PTX療法について
田原 良博, 細川 歩, 中島 孝治, 米澤 瑛美, 坂元 一樹, 山嶋 友実, 宮後 冴, 米澤 玲美, 黒木 大介, 野田 貴穂, 鈴木 翔, 久保田 良政, 松本 英丈, 芦塚 伸也, 安倍 弘生, 三池 忠, 坂 哲臣, 山本 章二朗, 稲津 東彦, 河上 洋
第114回日本消化器病学会九州支部例会
Event date： 2019.11.8 - 2019.11.9
Language：Japanese Presentation type：Symposium, workshop panel (public)
-
Pembrolizumabを投与したMSI-High大腸癌の1例
田村 穂高, 中島 孝治, 田原 良博, 細川 歩, 河上 洋
第114回日本消化器病学会九州支部例会
Event date： 2019.11.8 - 2019.11.9
Language：Japanese Presentation type：Oral presentation (general)
-
Methotrexate+5-fluorouracil療法が著効したDIC合併胃癌骨髄癌腫症の1例
井手 雄太郎, 米澤 瑛美, 田原 良博, 貴島 翔子, 坂元 一樹, 野田 貴穂, 鈴木 翔, 安倍 弘生, 三池 忠, 山本 章二朗, 中島 孝治, 日高 智徳, 細川 歩, 下田 和哉, 河上 洋
第114回日本消化器病学会九州支部例会
Event date： 2019.11.8 - 2019.11.9
Language：Japanese Presentation type：Oral presentation (general)
-
当院における切除不能進行・再発胃癌に対するニボルマブ療法の現状
米澤 玲美, 細川 歩, 中島 孝治, 田原 良博, 山嶋 友実, 宮後 冴, 松本 英丈, 芦塚 伸也, 稲津 東彦, 河上 洋
第114回日本消化器病学会九州支部例会
Event date： 2019.11.8 - 2019.11.9
Language：Japanese Presentation type：Oral presentation (general)
-
The results of Japanese subgroup analyses from TAGS: a phase 3 study of FTD/TPI (TAS-102) in heavily pretreated mGC
細川歩, 設樂 紘平, 西川和宏, 藤谷和正, 保坂尚志, 肥田圭介, 間狩洋一, 天貝賢二, 行澤 斉悟, 安藤 孝将, David H Ilson, Josep Tabernero, 土井 俊彦
第17回日本臨床腫瘍学会学術集会
Event date： 2019.7.18 - 2019.7.20
Language：English Presentation type：Oral presentation (general)
Past consigned research fund received 【 display / non-display 】
-
EFFECT OF TAS-116 ON CARDIOVASCULAR SAFETY PARAMETERS IN PATIENTS WITH ADVANCED SOLID TUMORS
2020.02 - 2020.12
Investigational New Drug Test
Consigned research type：Investigational New Drug Test